Temporary BTK Inhibitor Interruption Moves Into a Randomized CLL Vaccine Trial
Patients with chronic lymphocytic leukaemia often mount weak immune responses after vaccination, and the problem is especially relevant during the COVID-19 era. A multicentre UK trial now asks a focused clinical question: can a short pause in Bruton tyrosine kinase inhibitor therapy around a SARS-CoV-2 booster improve antibody production without destabilizing disease control?
The protocol is designed for an open-label, randomised controlled superiority study in haematology clinics at about 10 NHS hospitals. One hundred and twenty participants with CLL will be assigned 1:1 either to continue their BTK inhibitor as usual or to pause treatment for 3 weeks, beginning 1 week before booster vaccination. The intervention is narrow and deliberate. Investigators are not testing a long drug holiday or a broad treatment interruption strategy; they are testing whether a brief window of immune recovery can give the vaccine a better chance to work.
Why B-cell Signalling Matters at the Time of Vaccination
BTK inhibition suppresses a pathway that helps shape B-cell activation and antibody generation. In CLL, where immune dysfunction is already built into the disease biology, the combination can leave patients with poor serologic responses after vaccination. A booster dose can only do so much if the host immune machinery remains pharmacologically blunted at the moment antigen is presented.
The trial hypothesis follows directly from that mechanism. By stepping away from BTK inhibition for a short period, investigators are testing whether the immune system can respond more fully to the spike antigen delivered by vaccination. The biologic logic is straightforward: remove a targeted brake on B-cell signaling, then measure whether the humoral response improves at the time point most relevant to early vaccine priming.
Primary Endpoint Centers on Early Anti-Spike Antibody Production
The primary outcome is anti-spike receptor-binding domain antibody level at 3 weeks after SARS-CoV-2 booster vaccination. That endpoint places the focus on early immunogenicity rather than downstream clinical events, which are far harder to capture in a trial of this size. It also reflects the practical reality of vaccine studies in immunocompromised populations, where antibody kinetics often provide the clearest signal of biologic effect.
A 3-week readout will show whether the temporary interruption changes the early serologic response. If the paused arm develops a stronger antibody response, the result would support the idea that short, planned treatment breaks can create a more permissive immune environment during vaccination. If the two arms remain similar, the data would argue against benefit from interruption in this setting, at least for the outcome chosen here.
The design includes a second antibody assessment at 12 weeks postbooster, which may help determine whether any early advantage persists or fades with time. Persistence matters in CLL, where vaccine responses are often delayed, blunted, or both.
Safety Monitoring Extends Beyond Antibody Titres
This is not a single-laboratory study. The protocol also includes participant global assessments of disease activity, blood films, full blood count, lactate dehydrogenase levels, quality-of-life measures, and self-reported adherence with the request to pause or continue BTK inhibitor therapy. Those measures are clinically important because a vaccine-immunogenicity strategy cannot be separated from the underlying leukemia.
A brief interruption might be immunologically attractive, but it still has to be tolerated by patients who depend on continuous targeted therapy for disease control. The investigators are therefore watching for changes that could signal disease flare, altered blood counts, or biochemical evidence of shifting disease activity. That monitoring frame is essential in a population where the margin for therapeutic disruption can be narrow.
The study also plans to assess T-cell responses to spike protein and relative neutralising antibody titres against SARS-CoV-2 viral variants. Those readouts add depth to the immunology. Antibody quantity alone does not tell the whole story; neutralisation and cellular response can reveal whether the vaccine response is not only present, but potentially more functional.
Influenza Vaccination Adds a Real-World Layer
Another planned analysis examines whether there are effects in participants given influenza vaccination contemporaneously versus COVID-19 vaccination alone. That question is clinically relevant because immunocompromised patients often receive multiple seasonal vaccines within the same period. Parallel vaccination schedules are common in practice, but combined immune stimulation could complicate interpretation of response data. The trial’s ability to separate these patterns may help clinicians understand whether the BTK pause has a similar or different effect when vaccination is not limited to SARS-CoV-2 alone.
Randomisation, Analysis, and Internal Validity
Participants will be randomised in equal numbers to the intervention and usual care arms, and the primary analysis will follow the as-randomised groups on an intention-to-treat basis. The main comparison will use a mixed-effects regression model that accounts for repeated measures clustered within participants. The model will also adjust for line of therapy, distinguishing first-line from later-line treatment, and for prior infection status based on prerandomisation antinucleocapsid antibodies.
Those adjustments are methodologically sensible in CLL, where prior exposure to treatment and prior SARS-CoV-2 infection can both influence vaccine responses. The protocol does not overstate what statistical adjustment can do, but it does aim to reduce obvious confounding within the limits of a moderate-sized trial. A superiority framework fits the question being asked: does pausing therapy improve immune response enough to justify the risk and inconvenience of interruption?
Ethics Approval and Next Clinical Questions
Leeds East Research Ethics Committee and the Health Research Authority have approved the study. The trial is registered as ISRCTN14197181. Results will be shared through peer-reviewed publications, newsletters, conferences, and direct communication with participants, the CLL community, clinicians, and policy-makers.
For now, the protocol leaves one central issue unresolved in the real world: whether a short BTK inhibitor pause can improve vaccine immunogenicity without compromising leukemia management. The trial is built to answer that question with direct serologic and clinical data, not inference. In a population where both infection risk and treatment continuity matter, that balance will determine whether this strategy becomes part of routine vaccine planning or remains an unproven maneuver.